Switching the Smoothened Inhibitor May Have Benefit in Advanced Basal Cell Carcinoma

Am J Ther. 2018 May/Jun;25(3):e394-e396. doi: 10.1097/MJT.0000000000000721.

Authors

Bilal Khalid¹, Sarbajit Mukherjee¹, Sami Ibrahimi¹, Trinitia Cannon², Elizabeth Gilles³, Annie Moreau⁴, Mohammad Razaq¹

Affiliations

¹ Department of Medicine, Hematology-Oncology Section, The University of Oklahoma Health Sciences Center, Oklahoma City, OK.
² Departments of Otorhinolaryngology and.
³ Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK.
⁴ Department of Ophthalmology, The University of Oklahoma Health Sciences Center, Dean McGee Eye Institute, Oklahoma City, OK.

PMID: 29557803
DOI: 10.1097/MJT.0000000000000721

No abstract available

Publication types

Case Reports

MeSH terms

Anilides / therapeutic use*
Antineoplastic Agents / therapeutic use*
Basal Cell Carcinoma / drug therapy*
Biphenyl Compounds / therapeutic use*
Humans
Male
Middle Aged
Pyridines / therapeutic use*
Skin Neoplasms / drug therapy*
Smoothened Receptor / therapeutic use*
Treatment Outcome

Substances

Anilides
Antineoplastic Agents
Biphenyl Compounds
HhAntag691
Pyridines
SMO protein, human
Smoothened Receptor
sonidegib